Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts

G P Thomas, S U K Baker, J A Eisman and E M Gardiner

Bone and Mineral Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia

(Requests for offprints should be addressed to G P Thomas, Bone and Mineral Research Program, Garvan Institute of Medical Research, 384 Victoria St, Sydney, New South Wales 2010, Australia; Email: g.thomas@garvan.org.au)

Abstract

Osteoblast–osteoclast coordination is critical in the maintenance of skeletal integrity. The modulation of osteoclastogenesis by immature cells of the osteoblastic lineage is mediated through receptor activator of NFκB (RANK), its ligand RANKL, and osteoprotegerin (OPG), a natural decoy receptor for RANKL. Here, the expression of OPG and RANKL in primary mouse osteoblastic cultures was investigated to determine whether the osteoclastogenic stimulus depended on the stage of osteoblastic differentiation and the presence of the calcitrophic hormone 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3).

OPG mRNA expression was increased in osteoblastic cultures after the onset of mineralisation relative to less mature cultures, but did not alter in response to 1,25-(OH)2D3 treatment. In contrast, basal RANKL mRNA expression did not change during differentiation but was significantly enhanced by 1,25-(OH)2D3 treatment at all times. The stimulatory effects of 1,25-(OH)2D3 on RANKL were lessened in more mature cultures, however. The RANKL/OPG ratio, an index of osteoclastogenic stimulus, was therefore increased by 1,25-(OH)2D3 treatment at all stages of osteoblastic differentiation, but to a lesser degree in cultures after the onset of mineralisation. Thus the 1,25-(OH)2D3-driven increase in osteoclastogenic potential of immature osteoblasts appears to be mediated by increased RANKL mRNA expression, with mature osteoblasts having relatively decreased osteoclastogenic activity due to increased OPG mRNA expression. These findings suggest a possible mechanism for the recently proposed negative regulatory role of mature osteoblasts on osteoclastogenesis and indicate that the relative proportions of immature and mature osteoblasts in the local microenvironment may control the degree of resorption at each specific bone site.

Journal of Endocrinology (2001) 170, 451–460

Introduction

Skeletal structure is continually adapting to metabolic and mechanical demands. Osteoblastic (bone forming) and osteoclastic (bone resorbing) cells maintain the integrity of bone during this remodelling process, with tight regulation and coordination of their activities. In vivo histological and in vitro culture studies suggested a role for osteoblastic cells in the direct regulation of osteoclast activity (Rodan & Martin 1981, Martin & Ng 1994).

Resorption is stimulated by a number of factors, including the hormones 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) and parathyroid hormone (Teti et al. 1998, Flanagan et al. 1995, Suda et al. 1997). Enhancement of osteoclast differentiation and activity by 1,25-(OH)2D3 is largely mediated via the immature cells of the osteoblastic lineage (Martin & Ng 1994). Regulatory factors involved in this interaction have been identified. Stromal and osteoblast precursor cells express a member of the tumour necrosis factor ligand family, receptor activator of NFκB ligand (RANKL), also identified as osteoclast differentiation factor (ODF), osteoprotegerin ligand (OPG-L) and tumour necrosis factor-related, activation-induced cytokine (TRANCE) (Anderson et al. 1997, Wong et al. 1997, Lacey et al. 1998, Yasuda et al. 1998b). This cell-surface ligand stimulates osteoclastogenesis and osteoclast activity by binding to its cognate receptor, RANK, also termed ODF receptor (ODFR), on the surface of osteoclast precursors (Hsu et al. 1999). Addition of the cleaved and thus soluble form of RANKL can increase osteoclast formation and activity in vitro (Lacey et al. 1998, Matsuzaki et al. 1998, Yasuda et al. 1998b, Burgess et al. 1999). A further level of regulation is provided by the production of a RANKL ‘decoy receptor’, osteoprotegerin (OPG) or osteoclastogenesis inhibitory factor (OCIF), by osteoblasts and other cell types (Simonet et al. 1998, Yasuda et al. 1998a). OPG binds to RANKL, blocking its interaction with RANK on osteoclast precursors and thus inhibiting osteoclast activity (Lacey et al. 1998, Yasuda et al. 1998b, Hsu et al. 1999). The importance of this pathway has been demonstrated in OPG knockout mice, which exhibit severe osteoporosis (Bucay et al. 1998, Suda et al. 1998, Yasuda et al. 1998b).
Mizuno et al. (1998), and transgenic mice overexpressing OPG, which have osteopetrosis (Simonet et al. 1997). On the basis of these and other studies, it has been suggested that the ratio between RANKL and OPG expression levels in osteoblastic cells is a key factor in osteoclast regulation (Horwood et al. 1998, Nagai & Sato 1999).

Previous in vitro studies of OPG/RANK/RANKL regulation have utilised stromal cells, immature primary osteoblasts and osteoblast cell lines (Horwood et al. 1998, Hofbauer et al. 1999, Lee & Lorenzo 1999, Nagai & Sato 1999, Shirai et al. 1999, Suda et al. 1999, Yasuda et al. 1999, Deyama et al. 2000). Immature osteoblasts and stromal cells enhance osteoclast recruitment and differentiation (Martin & Ng 1994). Recent studies using cell lines induced to differentiate into a more mature osteoblastic phenotype have indicated that levels of expression of RANKL and OPG may be altered (Shirai et al. 1999, Deyama et al. 2000). However, the patterns of expression of RANKL and OPG have not been established during primary osteoblastic differentiation.

Primary osteoblasts cultured in vitro progress through a developmental sequence considered to mirror the sequence in vivo, with three overlapping stages of osteoblast differentiation and characteristic patterns of gene expression (Robey & Tremine 1985, Marie et al. 1989, Owen et al. 1990, Lian et al. 1990). Collagen type 1α1 (COL1; the main structural component of the bone extracellular matrix), is expressed from an early stage during osteoblast differentiation (Owen et al. 1990). Expression of non-collagenous matrix proteins such as osteopontin (OPN) and alkaline phosphatase (ALP), which are believed to stabilise the matrix, is associated with the matrix formation/maturation phase of differentiation (Owen et al. 1990, Stein & Lian 1993). Osteocalcin, the non-collagenous matrix protein expressed almost exclusively in bone, is up-regulated at the late stage of differentiation coincident with the onset of mineralisation, and thus is believed to have a role in the regulation of this process (Owen et al. 1990, Ducy et al. 1996). The effects of 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) on osteoblasts have been well characterised in rat and human osteoblastic cultures, with both stimulation and inhibition of genes associated with the differentiated osteoblastic phenotype, but an overall inhibitory effect on osteoblast differentiation, particularly by longer-term treatment (Au‘nmolk et al. 1985, Owen et al. 1991, Ishida et al. 1993, Siggelkow et al. 1999).

The present study examined primary mouse osteoblasts throughout their developmental sequence and their response to 1,25-(OH)2D3 treatment. Basal and 1,25-(OH)2D3-stimulated expression patterns of mouse genes encoding bone structural proteins and osteoclastogenic regulators were examined. RANKL mRNA expression was stimulated by 1,25-(OH)2D3 at all times, but was down-regulated in untreated late cultures. In contrast, OPG mRNA expression was increased at the onset of mineralisation and remained high throughout, thereby resulting in a lower RANKL/OPG ratio in mature osteoblasts. These changes in gene expression correlate with the previously proposed lower osteoclastogenic potential of mature osteoblasts in mice and suggest that immature and mature osteoblasts may have different roles in the maintenance of the bone remodelling balance.

Materials and Methods

Cell culture

Primary calvarial osteoblast cultures were established from 2-day-old FVB/N mice by enzymatic digestion (Wong & Cohn 1975), as described previously (Thomas et al. 2000). Briefly, frontal and parietal bones were removed, minced, transferred to digest mix (1 mg/ml collagenase (Boehringer-Mannheim, Mannheim, Germany), 0·05% trypsin (CSL, Sydney, Australia), 0·02% EDTA (ICN, Costa Mesa, CA, USA) in PBS, 1 ml/5 calvaria) and stirred for 30 min at 37 °C. Cells released from the first digest were discarded and the cells released from the second digest were seeded at a density of 104 cells per cm2 into six-well plates and cultured in α-MEM (Trace, Sydney, Australia) containing 10% fetal calf serum (Gibco, Grand Island, NY, USA), 100 U/ml penicillin, 100 mg/ml streptomycin, 40 mg/ml gentamycin, 20 mM HEPES, 2 mM glutamine (all Gibco), 10 mM β-glycerophosphate, 50 mg/ml ascorbic acid (Sigma, St Louis, MO, USA). Culture medium was changed after 3 days and every 2–3 days thereafter.

Cells were treated with 10−8 M 1,25-(OH)2D3 or 0·1% isopropanol vehicle at the time-point indicated and collected for analysis 48 h later.

Biochemical determinations

Cells were lysed in 0·5 ml/well of 0·1% Triton-X100, 0·5 mM MgCl2 in 20 mM Tris base, pH 10 and stored at −20 °C until required for assay.

DNA was assayed using a fluorimetric assay (Downs & Wilfinger 1983, Rao & Otto 1992). Briefly, 0·05 ml lysate was mixed with 0·2 ml of 1 mg/ml bishenzimide in water in clear polystyrene 96-well plates in duplicate, allowed to stand for 5 min, then read on a Fluoroskan II (Labsystems, Helsinki, Finland) with excitation at 355 nm and emission at 460 nm. DNA values were calculated using the Delta-Soft analytical software (Biometallics, Princeton, NJ, USA) and expressed as µg DNA.

ALP concentrations in the cell lysates were assayed by colourimetry (Lowry et al. 1954). Lysate (0·25 ml) was incubated at 37 °C for 15 min with 0·075 ml AMP buffer (0·075 M AMP 221 buffer (Sigma), 10 mM MgCl2, 2 mg/ml p-nitrophenol phosphate) in clear polystyrene 96-well plates. NaOH (0·1 ml of 0·5 M) was added to stop
the reaction and the plates were read at 405 nm. ALP concentrations were calculated against a p-nitrophenol standard curve. Values are expressed as mol p-nitrophenol produced per µg DNA per h.

Osteocalcin concentrations in the culture medium were determined by radioimmunoassay (Gundberg et al. 1992) in 50 µl samples and expressed as ng osteocalcin per µg DNA. Primary antibody and osteocalcin standards were kindly provided by C Gundberg (New Haven, CT, USA). Iodinated osteocalcin was purchased from Bio-technical Technologies Inc., Stoughton, MA, USA. Donkey anti-goat IgG secondary antibody was purchased from Sigma.

**RNA isolation and analysis**

RNA was isolated from osteoblastic cell cultures in six-well plates using 1 ml/well of Trizol reagent (Gibco) with 5 µg glycogen as carrier. RNA (15 µg) was analysed by reverse transcriptase (SuperScript II, Gibco) with random hexamer primers. PCR cDNAs were generated by reverse transcriptase (SuperScript II, Gibco) with random hexamer primers. PCR amplification was carried out with gene-specific primers (Sigma) using Taq polymerase (Amplitaq, Perkin Elmer, Norwalk, CT, USA). Reactions were carried out in foil-sealed 96-well plates (Thermofast 96, ABGene, Epsom, Surrey, UK) on a GeneAmp 9700 machine (Perkin Elmer). Both OPG and RANKL were duplicated with GAPDH after conditions were optimised to produce linear amplification for both genes. For both OPG–GAPDH and RANKL–GAPDH, annealing temperatures were 65 °C with the reactions run for 29 cycles. Specific primers were as follows: OPG (product 578 bp) forward 5′-TCTTGGCACCTGCTTAAAAACAGCA-3′, reverse 5′-CTACACTTGGGAGCTTACCTTGGG-3′; RANKL (product 394 bp) forward 5′-CACACCTACCATCAATGGC-3′, reverse 5′-GAAGGTTGAGCAGCAGTG-3′; GAPDH (product 983 bp) forward 5′-GTTGCGTGTTGAACGGATATTGGG-3′, reverse 5′-ATGGAGGCTGAGTGTGCGACACC-3′. PCR products were run on 1.5% agarose gels, stained with ethidium bromide, the image captured using GelDoc (BioRad, Hercules, CA, USA) and the bands quantified using MolecularAnalyt software (BioRad). Data are represented as the ratio to GAPDH PCR product.

**Statistical analysis**

Data shown are from at least two separate culture experiments and are the means of four to six replicates in each experiment for biochemical determinations. For RNA analysis, three experiments were conducted with two to six replicates in each experiment. Statistical comparisons were carried out by ANOVA using SuperAnova software (Abacus Concepts, Berkeley, CA, USA).

**Results**

**Osteoblast phenotype**

FVB/N primary mouse osteoblasts progressed through the osteoblastic developmental sequence, reaching confluence after approximately 10 days of culture, followed by matrix formation and maturation. At approximately 10 days post-confluence, mineralisation was detectable and continued for a further 20 days (as determined by visual inspection). These phases were reflected in the patterns of expression of key genes such as COL1, ALP, osteopontin and osteocalcin, and in mineralisation (Fig. 1). Osteopontin mRNA expression was evident at confluence and did not change significantly throughout the culture period. COL1 mRNA expression was high at confluence and decreased markedly by 10 days post-confluence before increasing at 20 and 30 days post-confluence. Although osteocalcin protein was measurable at confluence, its mRNA was negligible by northern blot analysis at this time-point. The increase in osteocalcin mRNA at later times (20 and 30 days post-confluence) was not as marked as the increase in osteocalcin protein. The ALP protein profile was similar to that of osteocalcin protein. Mineralisation, as measured by uptake of calcium-45, was low during the matrix maturation phase (8 days post-confluence) but increased through days 17 to 25 days post-confluence (Fig. 1).

The effects of short-term 1,25-(OH)2D3 treatment on expression of individual genes varied (Fig. 1). Osteocalcin RNA was reduced at all times post-confluence and osteocalcin protein was decreased by 20 days post-confluence. Osteopontin mRNA was strongly up-regulated by 1,25-(OH)2D3 throughout the culture period. In contrast, there was no consistent effect of 1,25-(OH)2D3 on COL1 mRNA expression. ALP protein was decreased after 1,25-(OH)2D3 treatment at both time-points post-confluence. Short-term (2 day) treatment with 1,25-(OH)2D3 inhibited mineralisation at 8 and 17 days post-confluence.

**Osteoclastogenesis regulatory genes**

RANKL RNA levels, measured by semi-quantitative RT-PCR, were evident at confluence, increased at 10 days post-confluence, then returned to confluence values at 20 days and remained low at 30 days post-confluence.
Figure 1 Osteoblast gene expression in primary osteoblast cultures. (A) Northern blot showing expression of genes in basal conditions and in 1,25-(OH)2D3-treated osteoblasts, at various stages during the culture period. Large changes in osteocalcin (OCN) and osteopontin (OPN) in response to 1,25-(OH)2D3 treatment are evident. Data are from duplicate wells. On longer exposures (not shown), signal was evident in all lanes of vehicle-treated cultures. (B) Expression of the osteocalcin gene was low at confluence and increased as differentiation progressed and was decreased significantly by 1,25(OH)2D3 treatment at all time-points post-confluence. Osteopontin RNA levels were relatively stable throughout the time course and were significantly increased by 1,25(OH)2D3 treatment at all time-points. COL1 (Collagen type 1) RNA expression was high at confluence, decreased by 10 days post-confluence then increased again by 30 days post-confluence, but showed no response to 1,25(OH)2D3 treatment. (C) Osteocalcin and ALP (Alkaline phosphatase) protein levels both increased markedly after the onset of mineralisation (beyond 10 days post-confluence). Treatment with 1,25(OH)2D3 decreased osteocalcin protein at 20 days post-confluence and ALP at 10 and 20 days post confluence. Mineralisation increased with the progression of differentiation in the cultures and was significantly inhibited by 1,25(OH)2D3 treatment at 8 and 17 days, but not 25 days post-confluence. Note the different time-points of the experiments. Cont (—), vehicle-treated; Treat (— – –), 1,25-(OH)2D3-treated. Values are means ± S.E.M. of two or three experiments with two to four replicates. *P<0.05, **P<0.01, 1,25-(OH)2D3-treated compared with vehicle-treated cultures.
OPG RNA was evident at confluence, increased by 10 days post-confluence and remained at a similar level thereafter (Fig. 2).

The effects of 1,25-(OH)_2D_3 treatment on expression of RANKL and OPG mRNAs were examined at various times up to 30 days post-confluence (Fig. 3). RANKL mRNA expression was increased by 1,25-(OH)_2D_3 treatment at all time-points. This was in contrast to OPG mRNA expression, which did not change in response to 1,25-(OH)_2D_3 treatment. As a consequence, the RANKL/OPG ratio was increased significantly by 1,25-(OH)_2D_3 treatment at all time-points, but to a lesser extent in the more mature primary osteoblastic cells.

Discussion

Expression of RANKL and OPG, key osteoclast regulatory genes, has previously been characterised predominantly in immature non-mineralising osteoblasts. In the present study, osteoblastic development through to mature mineralising cells was examined in primary cultures, as were the effects of 1,25-(OH)_2D_3 treatment on gene expression during this differentiation sequence. The developmental profile of mouse primary osteoblasts has been described previously (Lian et al. 1997, Thomas et al. 2000), although RANKL and OPG gene expression in fully mature mineralising primary osteoblastic cultures have not been studied.

The three osteoblastic developmental phases (Owen et al. 1991) can be clearly delineated, with the initial proliferative phase during which COL1 and osteopontin mRNA expression were evident, followed by the matrix production and maturation phase in which expression of the non-collagenous proteins osteopontin, ALP and osteocalcin were increased. The final mineralisation phase was marked by the increase in 45Ca uptake concomitant with

Figure 2 Levels of expression of osteoclastic regulatory molecules (RANKL and OPG) during osteoblast development in primary cultures. (A) Representative semi-quantitative RT-PCR for RANKL and OPG at 10 days post-confluence with and without 1,25-(OH)_2D_3 treatment. The upper band represents GAPDH (983 bp) and the lower band RANKL (394 bp) or OPG (578 bp). (B) RANKL and OPG RNA levels in untreated cultures, detected by semi-quantitative RT-PCR. RANKL expression increased between confluence and 10 days later, then returned to basal values at 20 and 30 days post-confluence. OPG expression increased by 10 days post-confluence relative to levels at confluence and remained increased at 20 and 30 days post-confluence. Values are means ± S.E.M. of three experiments with two to six replicates. *P<0·05, **P<0·01, time-point compared with confluent cultures.
Figure 3 Effects of short-term 1,25(OH)₂D₃ treatment on RANKL and OPG expression levels in osteoblastic cultures, measured by semi-quantitative RT-PCR. RANKL expression was up-regulated at all time-points by 1,25(OH)₂D₃ treatment. OPG expression was unaffected by 1,25(OH)₂D₃ treatment. RANKL/OPG ratios were increased at confluence by 48 h of treatment with 10⁻⁸M 1,25(OH)₂D₃. At later time-points the increase was less marked. —, Vehicle-treated cultures; –––, 1,25-(OH)₂D₃-treated cultures. Values are means ± S.E.M. of three experiments with two to six replicates. *P<0.05, **P<0.01, 1,25-(OH)₂D₃-treated compared with vehicle-treated cultures.
further up-regulation of osteocalcin production. This differentation profile is similar to that of other species (Robey & Termine 1985, Marie et al. 1989, Owen et al. 1990). The increase in COL1 mRNA expression observed during the later stages of osteoblast differentiation is consistent with a number of other studies in differentiated mouse, but not rat, osteoblasts (Owen et al. 1991, Yamashita et al. 1996, Lian et al. 1997, Qu et al. 1998).

As for other species, 1,25-(OH)2D3 treatment suppressed mineralisation of these primary mouse osteoblasts. Changes in gene expression were also consistent with earlier studies, including the inhibition of osteocalcin expression (Clemens et al. 1997, Lian et al. 1997, Sims et al. 1997, Zhang et al. 1997, Thomas et al. 2000) and up-regulation of osteopontin expression (Beresford et al. 1994, Owen et al. 1991, Lian et al. 1997). Short-term 1,25-(OH)2D3 treatment had no significant effect on COL1 mRNA expression, consistent with previous studies in mice and other species reporting only minimal differing responses to 1,25-(OH)2D3 (Kurihara et al. 1984, Lian et al. 1997, Siggelkow et al. 1999). ALP protein was down-regulated by 1,25-(OH)2D3 at all time-points measured, consistent with reports in rat primary osteoblasts (Owen et al. 1991), but contrasting with its up-regulation by 1,25-(OH)2D3 in the mouse osteoblastic MC3T3-E1 cell line (Kurihara et al. 1984, Matsumoto et al. 1991). Studies in human primary osteoblasts and cell lines have documented both up-regulation (Murray et al. 1987, Beresford et al. 1994, Harris et al. 1995) and minimal effects (Marie et al. 1989) on ALP by 1,25-(OH)2D3. Although mouse bone cells exhibit osteoblastic morphology and general response to 1,25-(OH)2D3 treatment that are similar to those in other species, differences in patterns of expression of specific gene and responses to 1,25-(OH)2D3 do occur. The significance of these species differences remains to be elucidated.

RANKL, a stimulator of osteoclast differentiation and activity (Yasuda et al. 1998b, Burgess et al. 1999), and OPG, the inhibitor of osteoclastogenesis (Simonet et al. 1997, Yasuda et al. 1998a), were differentially expressed during osteoblast development. RANKL mRNA expression was detectable at confluence, increased transiently during matrix formation and initiation of mineralisation, then decreased in cells during the mineralisation phase. OPG mRNA expression was evident from confluence, increased during matrix production and maturation, and remained high in the mineralisation phase. The RANKL/OPG ratio, an index of osteoclast activation, did not alter significantly over the time-course of the study under basal conditions, with only a slight increase at the onset of mineralisation followed by a return to baseline as mineralisation progressed. Importantly, however, the RANKL/OPG ratio in response to 1,25-(OH)2D3 treatment decreased during maturation of these primary osteoblastic cultures. In this present study, protein levels of RANKL and OPG were not measured. However, recent studies have demonstrated that protein levels of RANKL and OPG closely correlate with mRNA levels in vitro (Holbauer et al. 1999, Deyama et al. 2000). Furthermore, RANKL and OPG mRNA levels have been shown to correlate with altered resorption in response to physiological stimuli such as calcium concentration (Yasuda et al. 1998b, Takeyama et al. 2000) and hormonal treatment (Lee & Lorenzo 1999), in pathologic states such as Paget’s disease of bone (Mena et al. 2000) and in a breast cancer bone metastasis model (Thomas et al. 1999).

Unlike the present study of mature mineralising osteoblastic cultures, previous in vitro characterisation of RANKL and OPG expression has focused on immature primary osteoblasts and osteoblastic cell lines. On the basis of these studies, it was previously suggested that regulation of RANKL and OPG by osteotropic agents such as 1,25-(OH)2D3 did not occur or was significantly reduced in more mature osteoblastic cell lines (Horwood et al. 1998, Nagai & Sato 1999). In the present study, however, a significant increase in the RANKL/OPG ratio was elicited by 1,25-(OH)2D3 treatment at all time-points, including the most mature cultures. The up-regulation of RANKL by 1,25-(OH)2D3 treatment was consistent with the known osteoclastogenic action of 1,25-(OH)2D3 and agrees with a number of recent reports in cell line and immature primary cells (Horwood et al. 1998, Yasuda et al. 1998b, Nagai & Sato 1999). OPG was not significantly altered by 1,25-(OH)2D3, contrasting with its down-regulation reported in previous studies in immature osteoblastic cells (Horwood et al. 1998, Murakami et al. 1998). The greater RANKL/OPG ratio in less mature 1,25-(OH)2D3-treated confluent cultures, driven by the lower OPG level at this time-point, is consistent with the osteoclastogenic activity of precursor stromal cells and early osteoblasts (Martin & Ng 1994). The decrease in the RANKL/OPG ratio in more differentiated cultures, whether under basal or 1,25-(OH)2D3-treated conditions, is driven primarily by the relative increase in OPG mRNA expression in mature osteoblasts, as there was little change in RANKL response to 1,25-(OH)2D3 during osteoblast development. The fact that OPG is a secreted polypeptide that may act locally or systemically, while RANKL is a cell-surface molecule and therefore can only act locally on neighbouring cells, may also influence this putative regulatory pathway. A recent study reported only partial site-specific rescue of osteopetrosis in RANKL-deficient mice by a lymphocyte-expressed RANKL transgene (Kim et al. 2001).

Recently, a decreased RANKL/OPG ratio in differentiated MC3T3.E1 osteoblasts was reported (Deyama et al. 2000). In that study, however, reduction of the RANKL/OPG ratio was driven by decreased expression of RANKL rather than by the increase in OPG expression seen here, possibly reflecting a difference between established cell lines and primary cultures. The differentiated MC3T3.E1 osteoblasts also exhibited decreased osteoclastogenic
potential (Deyama et al. 2000), consistent with a previously proposed negative regulatory effect of mature osteoblasts on osteoclast activity (Gardiner et al. 2000). Taken together, these data therefore suggest that altering the RANKL/OPG ratio may provide a simple reciprocal mechanism by which 1,25-(OH)2D3 could mediate both stimulation of osteoclastogenesis through immature stromal cells/osteoblasts, and the proposed inhibition of osteoclast activity by mature osteoblasts.

The mechanisms that define the locations at which bone resorption occurs throughout the skeleton have been unexplained. The present data suggest that physical proximity of osteoclastic precursors with both immature and mature osteoblasts may be an important aspect of local regulation of bone resorption during bone turnover.

Acknowledgements

This work was supported in part by grants from the NIH, USA, the National Health and Medical Research Council of Australia and AZA Research Pty Ltd. Care and treatment of all animals used to prepare primary cultures was in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (1997) and the Animal Research Act (NSW Agriculture) (1985).

References


Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT & Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. *Endocrine Reviews* 20 345–357.


Owen TA, Aronow MS, Barone LM, Bettencourt B, Stein GS & Lian JB 1991 Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. *Endocrinology* 128 1496–1504.


Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. PNAS 95 3597–3602.


Received 18 January 2001
Accepted 26 April 2001